Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Dyne Therapeutics (NasdaqGS:DYN) has initiated the Phase 3 Harmonia trial of DYNE-101 in myotonic dystrophy type 1, following alignment with the FDA on the study design. The Harmonia trial is a pivotal study focused on clinically meaningful endpoints tied to key functional impairments in myotonic dystrophy type 1. New long term data from the Phase 1/2 DELIVER trial of DYNE-251 in Duchenne muscular dystrophy report improvements in cardiac and lung function. These updates highlight clinical progress across Dyne's rare disease portfolio and potential future paths toward regulatory submissions. For investors watching rare disease drug developers, Dyne Therapeutics (NasdaqGS:DYN) is on many radars after a 48.7% return over the past year and a current share price of $17.92. The stock has also gained 20.6% over the past week and 7.4% over the past month, while year to
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Dyne Therapeutics (DYN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.MarketBeat
- Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case [Seeking Alpha]Seeking Alpha
DYN
Earnings
- 3/2/26 - Miss
DYN
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/11/26 - Form 4
- DYN's page on the SEC website